Neurocrine Biosciences reported second-quarter 2026 revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, driven by record sales of INGREZZA, CRENESSITY, and newly acquired VYKAT XR. The company also raised its full-year INGREZZA sales guidance and announced new senior appointments, including a Chief Business Officer, as it aims to build a broader multi-product neuroscience franchise. Despite the strong results, the stock fell 5.1%, with investors weighing near-term pricing and access risks, particularly around Medicare, and portfolio concentration on a few key products. The company's investment narrative projects US$5.1 billion in revenue and US$1.5 billion in earnings by 2029, with some analysts forecasting as much as US$6.4 billion in revenue and US$2.7 billion in earnings under more optimistic scenarios.
Neurocrine Biosciences IncInvestors weigh near-term pricing and access risks, particularly around Medicare, despite earnings beat and raised guidance.